Bruker Corporation develops and sells advanced spectroscopy and microscopy systems that enable scientific breakthroughs and quality control for life sciences and materials industries.
Bruker offers exposure to secular growth trends in biotechnology and advanced materials where its unique spectroscopy technology is indispensable for drug discovery and material characterization. The company's strong revenue trajectory over five years demonstrates resilient demand for its high-end instruments despite macroeconomic headwinds. Investors may value the potential for earnings recovery if debt restructuring eases pressure and R&D investments translate into new, higher-margin product launches.
The stock faces severe downside risk due to a prolonged period of net losses and a massive $2.36B retained earnings deficit that signals accumulated operational struggles. Heavy reliance on revolver financing with large repayments suggests liquidity constraints that could force asset sales or dilutive equity issuances if cash flow does not improve quickly. The high debt-to-equity ratio and recent decline in profitability make the stock vulnerable to rising interest rates or a slowdown in discretionary scientific spending.
Bruker Corporation is a global leader in spectroscopy, microscopy, and mass spectrometry solutions serving life sciences, materials science, and semiconductor markets. The company provides essential analytical instruments for R&D, quality control, and process optimization across academic and industrial sectors. With significant investments in research and development and a diverse product portfolio, Bruker supports critical scientific discovery and manufacturing efficiency worldwide.
Despite generating $3.44B in revenue, Bruker reported a net loss of $8.3M for 2025, driven by substantial debt repayments of $466.5M and other non-operating losses totaling $46.2M. The company continues to invest heavily with $395.2M in R&D and $90.8M in capital expenditures, yet operating cash flow of $134.1M was insufficient to cover the massive revolver repayments and dividend obligations. While revenue grew steadily from $2.53B in 2022 to $3.44B in 2025, profitability has eroded significantly as earnings fell from a peak of $428.5M in 2023 to a loss in the most recent period.
The global analytical instrumentation industry is characterized by high barriers to entry, requiring substantial capital expenditure for R&D and manufacturing of complex optical and magnetic systems. Market growth is driven by increasing demand for precision measurement in pharmaceutical development, semiconductor failure analysis, and environmental monitoring. Consolidation is common as larger players seek to expand their product portfolios through acquisitions, creating a competitive landscape where established brands hold significant market share.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $2.53B | $2.96B | $3.37B | $3.44B |
| Cost of Revenue | $1.23B | $1.45B | $1.72B | $1.86B |
| Gross Profit | $1.31B | $1.51B | $1.65B | $1.58B |
| Operating Expenses | $873.0M | $1.08B | $1.40B | $1.51B |
| Operating Income | $432.7M | $436.9M | $253.1M | $68.2M |
| R&D | $235.9M | $294.8M | $376.5M | $395.2M |
| G&A | $607.4M | $729.4M | $893.8M | $946.5M |
| Stock-Based Comp | $27.7M | $24.0M | $25.3M | $20.2M |
| D&A | $88.8M | $114.9M | $183.8M | $220.3M |
| Depreciation | $51.6M | $67.8M | $84.7M | $99.1M |
| Amortization | $37.1M | $47.1M | $99.1M | $121.2M |
| Other OpEx | $29.7M | $52.2M | $126.1M | $167.8M |
| Non-Operating Income | $-18.8M | $107.3M | $-46.2M | $-46.2M |
| Interest Expense | $16.1M | $16.4M | — | — |
| Interest Income | — | $7.5M | $9.3M | $14.8M |
| Pre-Tax Income | $413.9M | $544.2M | $206.9M | $22.0M |
| Income Tax | $116.4M | $117.7M | $91.4M | $29.3M |
| Continuing Ops | $297.5M | $426.5M | $115.5M | $-7.3M |
| Discontinued Ops | $1.0M | $2.0M | $-1.7M | $-1.0M |
| Net Income | $298.5M | $428.5M | $113.8M | $-8.3M |
| Minority Interest | $1.9M | $1.3M | $700.0K | $300.0K |
| Net to Common | $296.6M | $427.2M | $113.1M | $-8.6M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $2.11B | $2.16B | $2.05B | $2.21B |
| Cash & Equivalents | $645.5M | $488.3M | $183.4M | $298.8M |
| Marketable Securities | $0 | — | — | — |
| Accounts Receivable | $472.7M | $492.0M | $565.5M | $544.9M |
| Inventory | $800.1M | $968.3M | $1.07B | $1.09B |
| Other Current Assets | $194.9M | $215.6M | $236.5M | $274.2M |
| Long-Term Assets | $1.50B | $2.09B | $3.75B | $4.03B |
| PP&E (Net) | $487.0M | $599.7M | $669.3M | $744.8M |
| Intangibles | $270.9M | $330.5M | $912.5M | $899.6M |
| Goodwill | $457.6M | $582.6M | $1.51B | $1.55B |
| Operating Leases | $51.2M | $91.7M | $145.5M | $165.8M |
| Other LT Assets | $231.9M | $481.2M | $518.9M | $671.0M |
| Total Assets | $3.61B | $4.25B | $5.81B | $6.24B |
| Current Liabilities | $914.3M | $1.20B | $1.28B | $1.28B |
| Accounts Payable | $178.4M | $202.7M | $234.1M | $215.9M |
| Current Leases | $16.4M | $23.3M | $32.1M | $35.2M |
| Deferred Revenue | $218.0M | — | — | $441.3M |
| Taxes Payable | $85.5M | $138.7M | $119.6M | $76.2M |
| Other Current Liab | $416.0M | $837.4M | $895.5M | $499.1M |
| Long-Term Liabilities | $1.57B | $1.63B | $2.71B | $2.45B |
| Long-Term Debt | $1.20B | $1.16B | $2.06B | $1.85B |
| LT Operating Leases | $34.8M | $74.8M | $118.9M | $138.6M |
| Other LT Liab | $280.3M | $307.9M | $355.6M | $269.7M |
| Total Liabilities | $2.49B | $2.84B | $3.99B | $3.73B |
| Shareholders' Equity | $1.13B | $1.41B | $1.82B | $2.51B |
| Retained Earnings | $1.93B | $2.32B | $2.41B | $2.36B |
| AOCI | $14.8M | $6.0M | $-103.5M | $-79.5M |
| Treasury Stock | $1.08B | $1.24B | $1.24B | $1.24B |
| Total L&E | $3.61B | $4.25B | $5.81B | $6.24B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $298.5M | $428.5M | $113.8M | $-8.3M |
| Non-Cash Adjustments | $-286.4M | $-298.6M | $153.9M | $359.8M |
| Working Capital Changes | $262.3M | $220.2M | $-16.4M | $-217.4M |
| Cash from Operations | $274.4M | $350.1M | $251.3M | $134.1M |
| Capital Expenditures | $129.2M | $106.9M | $115.3M | $90.8M |
| Cash from Investing | $-251.6M | $-326.0M | $-1.76B | $-196.5M |
| Debt Issuances | $0 | — | $973.7M | $3.5M |
| Debt Repayments | — | — | $135.4M | $466.5M |
| Share Buybacks | $263.1M | $152.3M | $0 | $10.0M |
| Dividends Paid | $29.8M | $29.4M | $30.2M | $22.8M |
| Cash from Financing | $-415.3M | $-193.4M | $1.23B | $135.1M |
| FX Effect | $-30.5M | $12.2M | $-28.7M | $43.7M |
| Net Change in Cash | $-423.0M | $-157.1M | $-304.9M | $116.4M |
| Beginning Cash | $1.07B | $648.7M | $491.6M | $186.7M |
| Ending Cash | $648.7M | $491.6M | $186.7M | $303.1M |
The company's revenue streams are driven by its core analytical instrument lines including NMR, Mass Spectrometry, Microscopy, and X-Ray systems, which cater to both research institutions and industrial clients seeking high-precision measurement tools. Revenue also includes consumables, software licenses, and maintenance services associated with these sophisticated scientific platforms.
Significant debt levels, including $1.85B in long-term debt and a revolving credit facility, create refinancing risks given the company's recent net loss and limited cash flow from operations relative to interest obligations. The semiconductor and life sciences markets face cyclical downturns that could reduce demand for high-cost capital equipment during economic contractions. High concentration of goodwill ($1.55B) exposes the stock to impairment charges if acquired technologies or business units underperform expectations.
Bruker maintains a strong competitive moat through its proprietary technology in nuclear magnetic resonance (NMR) and mass spectrometry, which are difficult for competitors to replicate without decades of R&D investment. The company benefits from high switching costs for customers who rely on its specialized software ecosystems and established service networks for instrument maintenance. Its global presence and deep partnerships with leading universities provide early access to emerging scientific trends and new application development opportunities.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.